PSA response linked to improved survival with darolutamide triplet in mHSPC
June 8th 2022Overall survival was higher among patients with mHSPC who achieved undetectable PSA levels when treated with the triplet of darolutamide, ADT, and docetaxel, according to an analysis from the phase 3 ARASENS trial.
PSMA-PET criteria identified to optimize mCRPC patient selection for 177Lu-PSMA-617
June 5th 2022"PSMA-PET imaging reports on individual lesions of patients with mCRPC could include SUVmean prior to starting 177Lu-PSMA-617 therapy to provide important prognostic information on potential treatment responses and long-term outcomes," said Andrew J. Armstrong, MD.
Toripalimab active in urothelial carcinoma, predictive biomarkers emerge
June 4th 2022The PD-1 inhibitor toripalimab is approved in China for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.
Vibegron equally effective in OAB wet and dry patients
April 26th 2022“In this subgroup analysis of data from the EMPOWUR trial, vibegron was associated with significant reductions in urgency episodes and micturitions compared with placebo in both the OAB dry and wet populations,” said lead author Jeffrey Frankel, MD.
Novel TKI/immunotherapy combo shows promise in advanced kidney cancer
April 22nd 2022Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.
Enfortumab Vedotin approved in EU for urothelial cancer
April 14th 2022The approval was based on data from the phase 3 EV-301 trial, in which enfortumab vedotin reduced the risk of death by 30% versus chemotherapy in patients with heavily pretreated locally advanced or metastatic urothelial carcinoma.
Study launches of Cu-64 SAR-bisPSMA in biochemically recurrent prostate cancer
April 1st 2022Eligible patients for the multicenter, nonrandomized, single-arm trial (NCT05249127) will have suspected recurrence of prostate cancer as determined by a rising prostate-specific antigen following definitive therapy.